Evoke Pharma Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Evoke Pharma has been growing earnings at an average annual rate of 5%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 67.5% per year.
Anahtar bilgiler
5.0%
Kazanç büyüme oranı
22.2%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 6.0% |
Gelir büyüme oranı | 67.5% |
Özkaynak getirisi | -245.0% |
Net Marj | -86.7% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely
Jan 22Evoke to get US patent for nasal spray Gimoti
Sep 20Evoke Pharma Q2 GAAP loss per share narrows, revenue up
Aug 10Evoke Pharma gets Canadian patent linked to Gimoti nasal spray
Jul 06Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Oct 22Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Jul 06Evoke Pharma announces positive findings from second GIMOTI market research study
Jun 15Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Jun 08Evoke Pharma issued new U.S. patent covering methods of use for Gimoti
Jun 02Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit
Mar 14Gelir ve Gider Dağılımı
Evoke Pharma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 8 | -7 | 13 | 0 |
31 Mar 24 | 6 | -7 | 13 | 0 |
31 Dec 23 | 5 | -8 | 12 | 0 |
30 Sep 23 | 4 | -8 | 11 | 0 |
30 Jun 23 | 4 | -8 | 11 | 0 |
31 Mar 23 | 3 | -8 | 10 | 0 |
31 Dec 22 | 3 | -8 | 10 | 0 |
30 Sep 22 | 2 | -8 | 9 | 0 |
30 Jun 22 | 2 | -8 | 9 | 0 |
31 Mar 22 | 2 | -8 | 9 | 0 |
31 Dec 21 | 2 | -9 | 9 | 1 |
30 Sep 21 | 1 | -9 | 9 | 1 |
30 Jun 21 | 0 | -9 | 8 | 1 |
31 Mar 21 | 0 | -14 | 7 | 6 |
31 Dec 20 | 0 | -13 | 6 | 7 |
30 Sep 20 | 0 | -12 | 5 | 7 |
30 Jun 20 | 0 | -12 | 4 | 8 |
31 Mar 20 | 0 | -7 | 4 | 3 |
31 Dec 19 | 0 | -7 | 4 | 3 |
30 Sep 19 | 0 | -7 | 4 | 3 |
30 Jun 19 | 0 | -7 | 4 | 3 |
31 Mar 19 | 0 | -8 | 4 | 3 |
31 Dec 18 | 0 | -8 | 4 | 4 |
30 Sep 18 | 0 | -6 | 4 | 5 |
30 Jun 18 | 0 | -10 | 4 | 7 |
31 Mar 18 | 0 | -9 | 4 | 8 |
31 Dec 17 | 0 | -12 | 4 | 7 |
30 Sep 17 | 0 | -13 | 4 | 7 |
30 Jun 17 | 0 | -11 | 4 | 6 |
31 Mar 17 | 0 | -13 | 4 | 6 |
31 Dec 16 | 0 | -11 | 4 | 7 |
30 Sep 16 | 0 | -12 | 4 | 7 |
30 Jun 16 | 0 | -12 | 4 | 8 |
31 Mar 16 | 0 | -12 | 4 | 8 |
31 Dec 15 | 0 | -12 | 4 | 8 |
30 Sep 15 | 0 | -12 | 4 | 9 |
30 Jun 15 | 0 | -14 | 3 | 10 |
31 Mar 15 | 0 | -14 | 3 | 11 |
31 Dec 14 | 0 | -13 | 3 | 10 |
30 Sep 14 | 0 | -12 | 3 | 8 |
30 Jun 14 | 0 | -9 | 3 | 5 |
31 Mar 14 | 0 | -5 | 2 | 3 |
Kaliteli Kazançlar: EVOK is currently unprofitable.
Büyüyen Kar Marjı: EVOK is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: EVOK is unprofitable, but has reduced losses over the past 5 years at a rate of 5% per year.
Büyüme Hızlandırma: Unable to compare EVOK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: EVOK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Özkaynak Getirisi
Yüksek ROE: EVOK has a negative Return on Equity (-244.97%), as it is currently unprofitable.